(continued)
- FDA Approves Revuforj as a Targeted Oral Therapy for Relapsed or Refractory NPM1-Mutated Acute Myeloid Leukemia
- Gazyva: FDA Approves Antibody-Based Infusion Therapy for Adults With Lupus Nephritis
- Tezspire: FDA Approves New Option for Chronic Sinus Inflammation With Nasal Polyps
- Rybelsus: FDA Approves the Only Oral GLP-1 Medicine to Reduce Cardiovascular Risk in Adults with Type 2 Diabetes
- Uzedy: FDA Approves Once-a-Month Subcutaneous Injectable Risperidone for Bipolar I Disorder
- Jascayd: New Oral Therapy for Idiopathic Pulmonary Fibrosis in Adults
- Zoryve: FDA Expands Use of Once-Daily Steroid-Free Skin Cream for Children Ages 2-5 Years With Mild to Moderate Eczema
- FDA Expands Approval of Simponi for Use in Pediatric Patients with Ulcerative Colitis
- FDA Approves Combined Use of Zepzelca and Atezolizumab as First-Line Maintenance Treatment for Advanced Small-Cell Lung Cancer
- FDA Approves Palsonify: First Once-Daily Pill for Acromegaly in Adults
- Inluriyo: FDA Approves New Once-Daily Pill for ESR1-Mutated Advanced Breast Cancer in Patients Previously on Hormone Therapy
- Tremfya: First Fully Under-the-Skin IL-23 Inhibitor Shot Approved for Ulcerative Colitis and Crohn’s Disease
- Forzinity: New Once-Daily Shot Gets Accelerated FDA Nod for Boosting Muscle Strength in Barth Syndrome
- Keytruda Qlex: FDA Approves New Subcutaneous Immune Therapy Shot for Treating a Wide Range of Advanced Cancers
- FDA Approves Enbumyst: First and Only Nasal Spray Diuretic for Edema From Heart, Liver, and Kidney Diseases
- Opzelura: FDA Expands Use of Steroid-Free Skin Cream for Young Children With Eczema
- Vyjuvek Label Update: FDA Removes Lower Age Limit
- Ocaliva Pulled From U.S. Market for Liver Disease
- Inlexzo: A New Bladder Cancer Treatment
- FDA Expands Approved Use of Vonvendi
- FDA Approves At-Home Once-Weekly Leqembi Injection as Maintenance Therapy for Early Alzheimer's Disease
- Wayrilz: A New Twice-Daily Pill for Persistent and Chronic Immune Thrombocytopenia
- FDA Expands Repatha Approval
- Dawnzera: First RNA-Targeted Therapy to Prevent Hereditary Angioedema Attacks
- FDA Approves Wegovy as First Once-Weekly Injection for Obesity-Linked Liver Disease
- FDA Approves New Non-Opioid, Once-Daily Bedtime Tablet for Fibromyalgia Pain and Sleep Disturbance
- Brinsupri: First Once-Daily Tablet for Non-Cystic Fibrosis Bronchiectasis
- Hernexeos (Zongertinib) Approved as the First Oral Targeted Treatment for HER2-Mutant Advanced Lung Cancer
- Ajovy Approved as a First-of-Its-Kind Shot for Preventing Migraine in Children and Teens
- Vizz: New Daily Eye Drop to Improve Age-Related Blurry Near Vision